Profile: Illumina Inc (ILMN.O)
Illumina, Inc. (Illumina), incorporated on May 16, 2000, is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. GRAIL is engaged in developing a blood test for early-stage cancer detection. Helix was established to enable individuals to explore their genetic information by providing sequencing and database services for consumers through third-party partners.
The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company offers its products and services to various customers, including genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The Company's products and services enable the adoption of genomic solutions in research and clinical settings. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing. The Company's technology enables NIPT for early identification of fetal chromosomal abnormalities by analyzing cell-free deoxyribonucleic acid (DNA) in maternal blood. Its preimplantation genetic screening solution is used with in vitro fertilization (IVF) to determine, before implantation, whether an embryo has an abnormal number of chromosomes. Its preimplantation genetic diagnosis technology determines which embryos are free from gene variants associated with genetic diseases.
The Company provides whole-genome sequencing, genotyping, NIPT and support services. The Company's technology platforms support the scale of experimentation necessary for population-scale studies, genome-wide discovery, target selection, and validation studies. Its products are used to analyze the genome at all levels of complexity, from whole-genome sequencing to targeted panels. Its products include instruments and consumables (which include reagents, flow cells and microarrays). The Company's sequencing platforms are used to perform whole-genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes.
The Company's DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis (SBS) biochemistry. SBS tracks the addition of labeled nucleotides as the DNA chain is copied in a parallel fashion. Its sequencing platforms range between 500 megabases (Mb) and 2.0 terabases (Tb) of genomic data in a single run, depending on the instrument and application. Its BaseSpace Informatics Suite cloud platform supports its sequencing applications. The BaseSpace Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyzes the raw genomic data. It facilitates data sharing, provides data-storage solutions and streamlines analysis through various applications from it and the bioinformatics community. The Company's BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that performs multiple assays simultaneously. Its iScan array scanner system and NextSeq 550 system are used to image the arrays. The Company's array-based genotyping consumables are used for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.
The Company competes with Agilent Technologies, Inc., BGI, Oxford Nanopore Technologies Limited, Pacific Biosciences of California, Inc., QIAGEN N.V., Roche Holding AG. and Thermo Fisher Scientific, Inc.
5200 Illumina Way
SAN DIEGO CA 92122-4616
Company Web Links
- 'Liquid biopsy' spots early-stage cancers in blood: U.S. study
- 'Liquid biopsy' spots early-stage cancers in blood -U.S. study
- Illumina shares sparkle on strong demand for new gene tech
- CORRECTED-UPDATE 1-Illumina shares sparkle on strong demand for new gene tech
- Illumina shares sparkle on demand for new gene tech